It is therefore of great interest to note that both FGF19 and FGF21 analogues which often have been categorized as metabolic compounds, show NASH resolution and lower fibrosis in trials of relative short duration. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatohepatitis.